Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors
Candid Therapeutics, a clinical stage biotechnology company focused on T-cell engagers for autoimmune diseases, has appointed Angie You, Ph.D. and Dan Puckett to its board of directors. Dr. You, currently CEO of Architect Therapeutics, brings extensive experience in scaling organizations and advancing innovative products. She previously led Amunix Pharmaceuticals to a $1.2 billion acquisition by Sanofi. Mr. Puckett, former CFO of Shockwave Medical, played a key role in the company's growth leading to its $13.1 billion acquisition by Johnson & Johnson in 2024.
Ken Song, Chairman, President and CEO of Candid Therapeutics, expressed confidence that these proven leaders will be invaluable resources as the company aims to become a leader in treating autoimmune diseases. Both new board members have expressed enthusiasm for Candid's potential to transform autoimmune disease treatment through T-cell engagers.
Candid Therapeutics, una società biotecnologica in fase clinica focalizzata su engagers delle cellule T per le malattie autoimmuni, ha nominato Angie You, Ph.D. e Dan Puckett nel suo consiglio di amministrazione. La Dr.ssa You, attualmente CEO di Architect Therapeutics, porta una vasta esperienza nella scalabilità delle organizzazioni e nello sviluppo di prodotti innovativi. In precedenza ha guidato Amunix Pharmaceuticals fino a un'acquisizione da 1,2 miliardi di dollari da parte di Sanofi. Il Sig. Puckett, ex CFO di Shockwave Medical, ha svolto un ruolo chiave nella crescita dell'azienda che ha portato alla sua acquisizione da 13,1 miliardi di dollari da parte di Johnson & Johnson nel 2024.
Ken Song, Presidente e CEO di Candid Therapeutics, ha espresso fiducia nel fatto che questi leader esperti saranno risorse preziose mentre l'azienda mira a diventare un leader nel trattamento delle malattie autoimmuni. Entrambi i nuovi membri del consiglio hanno espresso entusiasmo per il potenziale di Candid di trasformare il trattamento delle malattie autoimmuni attraverso gli engagers delle cellule T.
Candid Therapeutics, una empresa de biotecnología en etapa clínica enfocada en engagers de células T para enfermedades autoinmunes, ha designado a Angie You, Ph.D. y Dan Puckett en su junta directiva. La Dra. You, actualmente CEO de Architect Therapeutics, aporta una amplia experiencia en la escalabilidad de organizaciones y en el avance de productos innovadores. Anteriormente, lideró Amunix Pharmaceuticals hasta su adquisición de 1.2 mil millones de dólares por parte de Sanofi. El Sr. Puckett, ex CFO de Shockwave Medical, desempeñó un papel clave en el crecimiento de la empresa que llevó a su adquisición de 13.1 mil millones de dólares por Johnson & Johnson en 2024.
Ken Song, Presidente y CEO de Candid Therapeutics, expresó confianza en que estos líderes probados serán recursos invaluables mientras la empresa busca convertirse en un líder en el tratamiento de enfermedades autoinmunes. Ambos nuevos miembros de la junta han expresado entusiasmo por el potencial de Candid para transformar el tratamiento de las enfermedades autoinmunes a través de los engagers de células T.
자기면역 질환을 위한 T세포 인게이저에 집중하는 임상 단계의 생명공학 회사인 Candid Therapeutics가 Angie You 박사와 Dan Puckett를 이사회에 임명했습니다. 현재 Architect Therapeutics의 CEO인 You 박사는 조직 확장 및 혁신적인 제품 개발에 대한 광범위한 경험을 지니고 있습니다. 그녀는 이전에 Amunix Pharmaceuticals를 이끌어 Sanofi에 의해 12억 달러에 인수되는 데 기여했습니다. Puckett 씨는 Shockwave Medical의 전 CFO로서, 2024년에 Johnson & Johnson에 의해 131억 달러에 인수되는 데 중요한 역할을 했습니다.
Candid Therapeutics의 회장 겸 CEO인 Ken Song은 이러한 검증된 리더들이 회사가 자기면역 질환 치료의 선두주자가 되는 데 invaluable한 자원이 될 것이라고 확신을 나타냈습니다. 새로운 이사회 멤버들은 T세포 인게이저를 통해 자기면역 질환 치료를 혁신할 수 있는 Candid의 잠재력에 대한 열정을 표명했습니다.
Candid Therapeutics, une entreprise de biotechnologie en phase clinique axée sur les engageurs de cellules T pour les maladies auto-immunes, a nommé Angie You, Ph.D. et Dan Puckett à son conseil d'administration. Dr. You, actuellement PDG d'Architect Therapeutics, apporte une vaste expérience dans l'évolution des organisations et le développement de produits innovants. Elle a précédemment dirigé Amunix Pharmaceuticals jusqu'à son acquisition par Sanofi pour 1,2 milliard de dollars. M. Puckett, ancien directeur financier de Shockwave Medical, a joué un rôle clé dans la croissance de l'entreprise, menant à son acquisition par Johnson & Johnson pour 13,1 milliards de dollars en 2024.
Ken Song, président et PDG de Candid Therapeutics, a exprimé sa confiance que ces leaders éprouvés seront des ressources précieuses alors que l'entreprise vise à devenir un leader dans le traitement des maladies auto-immunes. Les deux nouveaux membres du conseil ont exprimé leur enthousiasme quant au potentiel de Candid à transformer le traitement des maladies auto-immunes grâce aux engageurs de cellules T.
Candid Therapeutics, ein biotechnologisches Unternehmen in klinischer Phase, das sich auf T-Zell-Engager für Autoimmunerkrankungen konzentriert, hat Angie You, Ph.D. und Dan Puckett in seinen Vorstand berufen. Dr. You, derzeit CEO von Architect Therapeutics, bringt umfangreiche Erfahrung in der Skalierung von Organisationen und in der Entwicklung innovativer Produkte mit. Zuvor leitete sie Amunix Pharmaceuticals, das für 1,2 Milliarden Dollar von Sanofi übernommen wurde. Herr Puckett, ehemaliger CFO von Shockwave Medical, spielte eine Schlüsselrolle in der Wachstumsphase des Unternehmens, die zur Übernahme durch Johnson & Johnson für 13,1 Milliarden Dollar im Jahr 2024 führte.
Ken Song, Vorsitzender und CEO von Candid Therapeutics, drückte sein Vertrauen aus, dass diese bewährten Führungskräfte von unschätzbarem Wert sein werden, während das Unternehmen anstrebt, ein führendes Unternehmen in der Behandlung von Autoimmunerkrankungen zu werden. Beide neuen Vorstandsmitglieder haben ihre Begeisterung für das Potenzial von Candid zum Ausdruck gebracht, die Behandlung von Autoimmunerkrankungen durch T-Zell-Engager zu transformieren.
- Appointment of experienced industry leaders to the board of directors
- New board members have track records of successful company acquisitions (Amunix for $1.2B, Shockwave for $13.1B)
- Potential to strengthen Candid's leadership in T-cell engagers for autoimmune diseases
- Addition of expertise in scaling organizations and advancing innovative products
- None.
“T-cell engagers have the potential to tranform the treatment of many autoimmune diseases. Ken has assembled a world-class management team and an diverse portfolio of assets. I am excited to partner with him, the Candid board and management team to support the company in it’s ambitious growth plans,” said Dr. You.
“Ken and team have made tremendous progress in a very short timeframe. I believe Candid is well positioned to be the leader in developing T cell engagers for B-cell depletion. I’ve worked with Ken in the past and look forward to leveraging my background to help scale the company,” said Mr. Puckett.
“Angie and Dan are proven leaders with a track record of scaling organizations and advancing innovative products into development and commercialization. I have been fortunate to have worked with each of them in the past and am delighted to welcome them to our board of directors. They will both be an invaluable resource to Candid as we strive to build the leading company in treating autoimmune diseases,” said Ken Song, Chairman, President and CEO of Candid Therapeutics.
Dr. You is currently the CEO and a member of the board of directors of Architect Therapeutics, and serves on the board of directors of ORIC Pharmaceuticals (Nasdaq: ORIC) and Attovia Therapeutics. Prior to Architect, Dr. You served as CEO of Amunix Pharmaceuticals, where she orchestrated the acquisition of the company by Sanofi for over
Mr. Puckett served as the Chief Financial Officer of Shockwave Medical from April 2016 to February 2024, a role in which he played a pivotal part in the company’s growth that led to the eventual acquisition by Johnson & Johnson for
About Candid Therapeutics, Inc.
Candid Therapeutics is a clinical stage biotechnology company that aims to lead the industry in advancing T-cell engagers to treat a range of immunological conditions. With two distinct clincial stage assets that are each capable of depleting different B cell populations, Candid is focused on rapidly advancing each asset through clinical development. Established in 2024 and headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241016572335/en/
Arvind Kush
info@candidrx.com
Source: Candid Therapeutics, Inc.
FAQ
Who are the new board members appointed to Candid Therapeutics?
What is Candid Therapeutics' focus in biotechnology?
What notable achievements do the new board members bring to Candid Therapeutics?
How might these appointments impact Candid Therapeutics' future?
